Product Information
RITALIN LA 30 MG CAPSULE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $12.3878 per EA under NDC 00078037105. Its NADAC has been published 398 times since Nov 28, 2013.
FDA first approved this application on Jun 5, 2002. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078037105
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
10/22/2025
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA021284FDA Approved
6/5/2002
TE Code
AB1
On Market Since
6/5/2002
Pharmacological Classes
Price Statistics
The NADAC for RITALIN LA 30 MG CAPSULE has been published 398 times since Nov 28, 2013, and over the history we have for it it has risen 136.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3878 per EA |
|---|---|
| All-time high | $12.4219 (Mar 12, 2025) |
| All-time low | $5.2303 (Nov 28, 2013) |
| 52-week high | $12.3878 |
| 52-week low | $12.3878 |
| Median price | $9.4443 |
| Average price | $9.4461 |
| Largest weekly change | +25.1% (Apr 17, 2024) |
| Weeks tracked | 398 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 86% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RITALIN LA 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RITALIN LA 30 MG CAPSULE, manufactured by Novartis Pharmaceuticals Corporation, is $12.3878 per EA (NDC 00078037105), effective Sep 30, 2026.
How has the price of RITALIN LA 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RITALIN LA 30 MG CAPSULE has risen 136.8%. It has been tracked across 398 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RITALIN LA 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for RITALIN LA 30 MG CAPSULE has ranged from a low of $5.2303 (Nov 28, 2013) to a high of $12.4219 (Mar 12, 2025), with a median of $9.4443 per EA.
Are there cheaper alternatives to RITALIN LA 30 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE CD 30 MG CAP, is $1.7946 per EA — about 86% below RITALIN LA 30 MG CAPSULE.
Who manufactures RITALIN LA 30 MG CAPSULE?
RITALIN LA 30 MG CAPSULE (NDC 00078037105) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.